PASSALACQUA, GIOVANNI
 Distribuzione geografica
Continente #
EU - Europa 50.167
Totale 50.167
Nazione #
IT - Italia 50.167
Totale 50.167
Città #
Genova 41.056
Rapallo 4.536
Genoa 3.293
Vado Ligure 1.209
Bordighera 73
Totale 50.167
Nome #
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early and late phase reactions after allergen-specific challenge. 169
Immunoterapia specifica: una possibilità di gestione del rischio professionale da allergia al veleno di imenotteri 168
NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. 163
Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. 159
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 156
Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. 149
A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis 145
A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. 144
Adhesion molecules in allergy. 139
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. 138
Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. 136
Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. 136
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 136
CD4(+)IL-13(+) cells in peripheral blood well correlates with the severity of atopic dermatitis in children. 135
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 135
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 134
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 134
Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. 132
Local Side Effects of Sublingual and Oral Immunotherapy 132
Catching allergy by a simple questionnaire 132
Focus on cat allergen (Fel d 1): immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies. 132
A survey of clinical features of allergic rhinitis in adults. 131
Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. 130
Latex-jujube cross-reactivity: case report and immunological study. 128
The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge. 128
Fibrous invasive (Riedel's) thyroiditis with critical response to steroid treatment. 128
How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. 128
When allergic rhinitis is not only allergic. 128
A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects. 127
The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. 127
The asthma-rhinitis association: between the clinical hypothesis and the scientific theory. 126
Continuous versus on demand treatment with cetirizine for allergic rhinitis. 126
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. 126
Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. 125
Personalized medicine in allergy 125
Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. 124
Safety of sublingual immunotherapy with a monomeric allergoid in very young children. 123
Sublingual immunotherapy. 123
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 123
An update on the asthma-rhinitis link. 122
The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years 122
Sublingual and oral immunotherapy. 122
Allergic rhinitis and its impact on asthma update: allergen immunotherapy. 122
New insights in sublingual immunotherapy. 122
A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. 122
New perspectives in the treatment of allergic rhinitis and asthma in children 121
Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. 121
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. 121
Will sublingual immunotherapy offer benefit for asthma? 121
Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. 121
Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. 120
How much specific is the association between hymenoptera venom allergy and mastocytosis? 120
Sublingual immunotherapy for allergic rhinitis and conjunctivitis. 120
The classification of allergic rhinitis and its cytological correlate. 120
Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. 119
Exercise-induced anaphylaxis to grape. 119
The safety of monoclonal antibodies in asthma 119
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study 119
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 119
United airways disease: therapeutic aspects 118
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper 118
Nonsteroidal antiallergic treatments in allergic rhinitis. 118
Allergy and the bone: unexpected relationships. 118
Severe skin reaction due to excipients of an oral iron treatment. 118
Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. 117
Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. 117
Prevalence of allergy to Cypress. 117
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. 117
Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma 117
Current insights in allergen immunotherapy 117
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 117
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 117
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. 117
Basi Patogenetiche ed anatomopatologiche della flogosi allergica nell’asma bronchiale 116
Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. 116
Sublingual immunotherapy: update 2006. 116
Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites 116
Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. 116
Large local reactions from stinging insects: from epidemiology to management. 116
Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial 116
Aerobiologic diagnosis of brassicaceae-induced asthma. 115
New insights in allergen avoidance measures for mite and pet sensitized patients. A critical appraisal. 115
Dermatological powder as hidden cause of occupational allergy due to casein: a case report. 115
Treating the allergic patient: think globally, treat globally. 115
Allergic and non-allergic rhinitis in swimmers: clinical and cytological aspects. 115
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum ctla-4 and IL-10. 115
Nasal budesonide efficacy for nasal nitric oxide and nasal obstruction in rhinitis 115
Seasonal and perennial allergic rhinitis: is this classification adherent to real life? 115
Sublingual immunotherapy for allergic rhinitis: an update. 114
Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN) 114
Emerging drugs for perennial allergic rhinitis. 114
Nasal cytology: Methodology with application to clinical practice and research 114
Serum cytotoxic T lymphocyte-associated antigen 4 in hymenoptera venom allergy and its modulation by specific immunotherapy 114
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision 114
Seasonal rhinitis and azelastine: long- or short-term treatment? 113
Lower airway inflammation before and after house dust mite nasal challenge: An age and allergen exposure-related phenomenon. 113
General strategy for the management of bronchial asthma in pregnancy. 113
Effects of mometasone furoate on the quality of life: a randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire. 113
Rhinitis, rhinosinusitis and quality of life in children. 113
Adherence to sublingual immunotherapy in preschool children. 113
Totale 12.429
Categoria #
all - tutte 144.786
article - articoli 144.106
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 680
Totale 289.572


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202014.574 0 0 0 1.163 1.512 1.647 3.085 1.142 1.603 2.439 1.515 468
2020/20214.045 277 310 316 394 227 323 216 421 360 472 273 456
2021/20226.607 154 387 560 940 118 561 551 1.380 276 574 310 796
2022/20235.520 599 224 32 482 839 1.113 70 513 1.083 96 391 78
2023/20242.372 177 419 52 196 233 365 124 108 129 47 163 359
2024/20251.262 102 701 275 184 0 0 0 0 0 0 0 0
Totale 50.880